Announcements Trials
Browse Landscape

Status

Completed 97Active not recruiting 41Recruiting 33Terminated 32Withdrawn 17Unknown 14Not yet recruiting 7No longer available 4Suspended 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Expanded_access 4

Sponsor

Cancer Type

Dermatologic 3Genitourinary 1

Conditions

Melanoma 3Skin Neoplasms 1Progressive Metastatic Castrate Resistant Prostate Cancer 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
No longer available × trametinib × Clear all
NCT04489433 2025-12-18

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Novartis

No longer available
Dermatologic

Melanoma

NCT04544202 2024-11-12

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Novartis

No longer available
Dermatologic

Melanoma, Skin Neoplasms

NCT03386071 2019-01-16

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Jonsson Comprehensive Cancer Center

No longer available
Genitourinary

Progressive Metastatic Castrate Resistant Prostate Cancer

NCT02416232 2017-08-15

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

GlaxoSmithKline

No longer available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡